Business
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET BETHESDA, Md., March 22, 2023 (GLOBE NEWSWIRE)
About this update from Gain Therapeutics, Inc.
[{"type":"text","content":"Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET\nBETHESDA, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding sites and creating small molecule therapies, today announced that it will participate in a virtual panel discussion on recent advances in AI-enabled computational biology and the future of drug discovery. Gain’s Chief Technology Officer, Xavier Barril, Ph.D., will be joined by key opinion leaders Brandon Allgood, Ph.D., former Chief Artificial Intelligence Officer of Valo Health, and Jason Paragas, Ph.D., Founder and Venture Partner at Social Impact Capital Fund. The fireside chat, titled “Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts,” will take place on Wednesday, March 29, 2023 at 12:00 pm ET. Hartaj Singh, M.B.A., Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion. Discussion Topics Computational drug discovery for precision medicine – development of small molecules in more homogenous patient populationsMerits of a combination of knowledge-based approaches (ML) and physics-based approachesBig Pharma perspective: technological solutions to discover, design, and develop therapeuticsMixed solvents MD (MDmix) simulations in structure-based drug discovery and GANX’s proprietary site-directed enzyme enhancement therapy (See-Tx™) platform to discover new allosteric binding sitesAlignment of computation and biological experiments, e.g., GANX’s approach in GBA1-Parkinson’s and GBA1-Gaucher disease Panel Participants Brandon Allgood currently the Founder; Board Member of The Alliance For Artificial Intelligence In Healthcare (AAIH) (2019-Present). He was also the Chief AI Officer at Valo Health Inc. (09/2019-12/2022). Brandon was also the Co-Founder; CTO (02/2013-09/2019) and Director of Computational Science (03/2007-02/2013) at Numerate Inc. Brandon was also the Senior Software Engineer at Pharmix Corporation (07/2006-03/2007). He is an entrepreneur focused on applying machine learning (ML) and large scale computational methods to improve human health. Brandon's for...